$HBIO
HARVARD BIOSCIENCE INC Stock $hbio

$hbio Overview Financials Valuation SEC Filings Company Website

2016 Q4 Form 10-Q Financial Statement

#000117184316012917 Filed on November 03, 2016

Income Statement

Concept	2016 Q4	2016 Q3	2015 Q3
Revenue	$26.42M	$25.01M	$25.73M
YoY Change	-6.89%	-2.81%	1.11%
Cost Of Revenue	$14.31M	$13.32M	$14.01M
YoY Change	-7.35%	-4.91%	-0.01%
Gross Profit	$12.11M	$11.69M	$11.73M
YoY Change	-6.34%	-0.31%	2.48%
Gross Profit Margin	45.83%	46.75%	45.57%
Selling, General & Admin	$10.26M	$9.810M	$10.03M
YoY Change	-0.39%	-2.22%	21.72%
% of Gross Profit	84.76%	83.92%	85.56%
Research & Development	$1.160M	$1.309M	$1.426M
YoY Change	-24.18%	-8.2%	34.66%
% of Gross Profit	9.58%	11.2%	12.16%
Depreciation & Amortization	$990.0K	$1.090M	$1.060M
YoY Change	-22.05%	2.83%	13.98%
% of Gross Profit	8.18%	9.32%	9.04%
Operating Expenses	$13.23M	$12.50M	$12.50M
YoY Change	3.26%	0.02%	24.8%
Operating Profit	-$1.123M	-$813.0K	-$775.0K
YoY Change	-1093.81%	4.9%	-154.39%
Interest Expense	$170.0K	$142.0K	$204.0K
YoY Change	-206.25%	-30.39%	-14.64%
% of Operating Profit
Other Income/Expense, Net	$135.0K	-$67.00K	-$321.0K
YoY Change	-131.11%	-79.13%	-31.56%
Pretax Income	-$988.0K	-$880.0K	-$1.096M
YoY Change	207.79%	-19.71%	-214.64%
Income Tax	$332.0K	$758.0K	-$249.0K
% Of Pretax Income
Net Earnings	-$1.320M	-$1.638M	-$847.0K
YoY Change	-92.3%	93.39%	-233.81%
Net Earnings / Revenue	-5.0%	-6.55%	-3.29%
Basic Earnings Per Share	-$0.04	-$0.05	-$0.02
Diluted Earnings Per Share	-$0.04	-$0.05	-$0.02
COMMON SHARES
Basic Shares Outstanding	34.37M shares	34.33M shares	33.93M shares
Diluted Shares Outstanding		34.33M shares	33.93M shares

Balance Sheet

Concept	2016 Q4	2016 Q3	2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.600M	$5.300M	$6.100M
YoY Change	-16.42%	-13.11%	-77.15%
Cash & Equivalents	$5.596M	$5.345M	$6.090M
Short-Term Investments
Other Short-Term Assets	$4.175M	$4.463M	$5.070M
YoY Change	7.8%	-11.97%	24.82%
Inventory	$19.96M	$21.20M	$23.01M
Prepaid Expenses
Receivables	$15.75M	$15.12M	$15.59M
Other Receivables	$4.200M	$4.500M	$5.100M
Total Short-Term Assets	$45.47M	$46.15M	$52.32M
YoY Change	-10.04%	-11.79%	-19.5%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.296M	$5.267M	$5.934M
YoY Change	-27.21%	-11.24%	44.41%
Goodwill	$38.03M	$39.62M	$40.86M
YoY Change	-5.76%	-3.02%	13.69%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$128.0K	$112.0K	$349.0K
YoY Change	-15.79%	-67.91%	-2.79%
Total Long-Term Assets	$62.29M	$66.02M	$81.23M
YoY Change	-10.37%	-18.72%	14.21%
TOTAL ASSETS
Total Short-Term Assets	$45.47M	$46.15M	$52.32M
Total Long-Term Assets	$62.29M	$66.02M	$81.23M
Total Assets	$107.8M	$112.2M	$133.6M
YoY Change	-10.23%	-16.01%	-1.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.196M	$6.142M	$6.322M
YoY Change	-29.45%	-2.85%	23.96%
Accrued Expenses	$4.550M	$4.501M	$3.840M
YoY Change	13.16%	17.21%	-7.07%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.400M	$2.400M	$5.000M
YoY Change	0.0%	-52.0%	0.0%
Total Short-Term Liabilities	$14.60M	$14.44M	$17.27M
YoY Change	-24.44%	-16.38%	10.51%
LONG-TERM LIABILITIES
Long-Term Debt	$11.37M	$12.67M	$15.15M
YoY Change	-30.51%	-16.38%	-16.76%
Other Long-Term Liabilities	$3.200M	$2.600M	$4.600M
YoY Change	6.67%	-43.48%	-14.81%
Total Long-Term Liabilities	$11.37M	$12.67M	$15.15M
YoY Change	-30.51%	-16.38%	-16.76%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.60M	$14.44M	$17.27M
Total Long-Term Liabilities	$11.37M	$12.67M	$15.15M
Total Liabilities	$35.57M	$36.29M	$39.27M
YoY Change	-16.21%	-7.6%	-0.21%
SHAREHOLDERS EQUITY
Retained Earnings	-$116.0M	-$114.7M	-$94.58M
YoY Change	3.86%	21.28%	2.06%
Common Stock	$215.6M	$417.0K	$211.1M
YoY Change	1.74%	-99.8%	2.57%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares	7.746M shares	7.746M shares	7.746M shares
Shareholders Equity	$72.20M	$75.89M	$94.29M
YoY Change
Total Liabilities & Shareholders Equity	$107.8M	$112.2M	$133.6M
YoY Change	-10.23%	-16.01%	-1.89%

Cashflow Statement

Concept	2016 Q4	2016 Q3	2015 Q3
OPERATING ACTIVITIES
Net Income	-$1.320M	-$1.638M	-$847.0K
YoY Change	-92.3%	93.39%	-233.81%
Depreciation, Depletion And Amortization	$990.0K	$1.090M	$1.060M
YoY Change	-22.05%	2.83%	13.98%
Cash From Operating Activities	$1.720M	$3.440M	-$80.00K
YoY Change	-2.82%	-4400.0%	-113.33%
INVESTING ACTIVITIES
Capital Expenditures	-$530.0K	-$540.0K	-$660.0K
YoY Change	-22.06%	-18.18%	37.5%
Acquisitions
YoY Change
Other Investing Activities	$1.420M	$0.00	-$10.00K
YoY Change		-100.0%
Cash From Investing Activities	$890.0K	-$540.0K	-$670.0K
YoY Change	-230.88%	-19.4%	39.58%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-1.210M	-1.030M	-410.0K
YoY Change	4.31%	151.22%	-130.15%
NET CHANGE
Cash From Operating Activities	1.720M	3.440M	-80.00K
Cash From Investing Activities	890.0K	-540.0K	-670.0K
Cash From Financing Activities	-1.210M	-1.030M	-410.0K
Net Change In Cash	1.400M	1.870M	-1.160M
YoY Change	-2100.0%	-261.21%	-178.38%
FREE CASH FLOW
Cash From Operating Activities	$1.720M	$3.440M	-$80.00K
Capital Expenditures	-$530.0K	-$540.0K	-$660.0K
Free Cash Flow	$2.250M	$3.980M	$580.0K
YoY Change	-8.16%	586.21%	-46.3%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	672166	shares
CY2013Q1	hbio	Ddtl Threshold For Dollar For Dollar Reduction In Revolving Line DdtlThresholdForDollarForDollarReductionInRevolvingLine	10000000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	31782	shares
CY2016Q3	hbio	Lender Approval To Fund Acquisition With Cash Promissory Note In Excess Of Threshold LenderApprovalToFundAcquisitionWithCashPromissoryNoteInExcessOfThreshold	6000000	USD
CY2016Q3	hbio	Lender Approval To Fund Acquisition With Equity In Excess Of Threshold LenderApprovalToFundAcquisitionWithEquityInExcessOfThreshold	10000000	USD
CY2009Q3	hbio	Previous Approved Credit Facility PreviousApprovedCreditFacility	20000000	USD
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4018248	shares
CY2013Q1	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	50000000	USD
	hbio	Derivative Interest Rate Swap Effective Percentage DerivativeInterestRateSwapEffectivePercentage	1	pure
CY2016Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15115000	USD
CY2016Q3	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	0	USD
CY2016Q3	us-gaap	Other Assets Current OtherAssetsCurrent	4463000	USD
CY2016Q3	us-gaap	Assets Current AssetsCurrent	46154000	USD
CY2016Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5267000	USD
CY2016Q3	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	931000	USD
CY2016Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	18861000	USD
CY2016Q3	us-gaap	Goodwill Goodwill	39624000	USD
CY2016Q3	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	1227000	USD
CY2016Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	112000	USD
CY2016Q3	us-gaap	Assets Assets	112176000	USD
CY2016Q3	us-gaap	Secured Debt Current SecuredDebtCurrent	2374000	USD
CY2016Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	6142000	USD
CY2016Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	729000	USD
CY2016Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	218000	USD
CY2016Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4501000	USD
CY2016Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	478000	USD
CY2016Q3	us-gaap	Liabilities Current LiabilitiesCurrent	14442000	USD
CY2016Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	12668000	USD
CY2016Q3	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	2643000	USD
CY2016Q3	us-gaap	Liabilities Liabilities	36285000	USD
CY2016Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q3	us-gaap	Common Stock Value CommonStockValue	417000	USD
CY2016Q3	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	3.97
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.8
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	3.15
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	3.87
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.92
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	3.87
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1100547	shares
CY2009Q3	hbio	Interest Rate In Excess Of Libor On Credit Facility InterestRateInExcessOfLiborOnCreditFacility	0.03	pure
CY2016Q3	us-gaap	Line Of Credit Facility Remaining Borrowing Capacity LineOfCreditFacilityRemainingBorrowingCapacity	7800000	USD
CY2013Q4	hbio	Transferof Delayed Draw Down Term Loan Capacity To Revolver Capacity TransferofDelayedDrawDownTermLoanCapacityToRevolverCapacity	5000000	USD
	us-gaap	Derivative Instruments Gain Loss Reclassification From Accumulated Oci To Income Estimated Net Amount To Be Transferred DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred	15000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	276420	shares
CY2015Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1096000	USD
CY2016Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	386000	USD
CY2016Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-114710000	USD
CY2016Q3	us-gaap	Treasury Stock Carrying Basis TreasuryStockCarryingBasis	10668000	USD
CY2016Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	112176000	USD
CY2016Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	42119852	shares
CY2016Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34374345	shares
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14134000	USD
CY2015Q4	us-gaap	Secured Debt SecuredDebt	18733000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5345000	USD
CY2016Q3	us-gaap	Stockholders Equity StockholdersEquity	75891000	USD
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	12501000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-775000	USD
CY2015Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-249000	USD
CY2015Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-321000	USD
CY2015Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2016Q3	us-gaap	Deferred Tax Liabilities Current DeferredTaxLiabilitiesCurrent	0	USD
	dei	Trading Symbol TradingSymbol	HBIO
CY2016Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-847000	USD
CY2015Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2016Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	7745507	shares
CY2016Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2016Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	34374345	shares
	dei	Document Type DocumentType	10-Q
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	HARVARD BIOSCIENCE INC
	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5005000	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1309000	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1426000	USD
CY2016Q3	us-gaap	Restructuring Charges RestructuringCharges	-17000	USD
CY2015Q3	us-gaap	Restructuring Charges RestructuringCharges	376000	USD
CY2016Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	729000	USD
CY2015Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	70000	USD
CY2016Q3	us-gaap	Interest Expense InterestExpense	142000	USD
CY2015Q3	us-gaap	Interest Expense InterestExpense	204000	USD
CY2016Q3	us-gaap	Other Interest And Dividend Income OtherInterestAndDividendIncome	1000	USD
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-64000	USD
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-188000	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	2596000	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	2049000	USD
	us-gaap	Depreciation Depreciation	1173000	USD
	us-gaap	Depreciation Depreciation	1157000	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-25000	USD
	hbio	Non Cash Restructuring Charge NonCashRestructuringCharge	-27000	USD
	hbio	Non Cash Restructuring Charge NonCashRestructuringCharge	-79000	USD
	hbio	Amortization Of Catalog Costs AmortizationOfCatalogCosts	13000	USD
	hbio	Amortization Of Catalog Costs AmortizationOfCatalogCosts	8000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	59000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	3000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	72000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	58000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	455000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1024000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2145000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-754000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-735000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1310000	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	742000	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	407000	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-2785000	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	35000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-158000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-362000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	296000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2046000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	29000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	158000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	7000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-316000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3656000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1059000	USD
	us-gaap	Property Plant And Equipment Additions PropertyPlantAndEquipmentAdditions	920000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	4545000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-954000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6837000	USD
	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	3000000	USD
	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	4800000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	6738000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	6100000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	80000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1953000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-3658000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	621000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-443000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-769000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1399000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-8044000	USD
	us-gaap	Interest Paid InterestPaid	468000	USD
	us-gaap	Interest Paid InterestPaid	625000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	725000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	625000	USD
CY2016Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	9465000	USD
CY2016Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	935000	USD
CY2016Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	10831000	USD
CY2016Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	21984000	USD
CY2016Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	16717000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	1754000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1754000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	1647000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	1423000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	1216000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	3372000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	11166000	USD
CY2016Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2600000	USD
CY2016Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2500000	USD
CY2016Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2300000	USD
CY2016Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2200000	USD
CY2016Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	2100000	USD
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2016Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-2006000	USD
CY2015Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-526000	USD
CY2016Q3	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	11000	USD
CY2015Q3	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-39000	USD
CY2016Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-8000	USD
CY2015Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-22000	USD
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3625000	USD
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1390000	USD
CY2016Q3	hbio	Total Indefinite Lived Intangible Assets Including Goodwill TotalIndefiniteLivedIntangibleAssetsIncludingGoodwill	40851000	USD
CY2016Q3	hbio	Total Intangible Assets TotalIntangibleAssets	88030000	USD
CY2016Q3	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	156000	USD
CY2016Q3	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	168000	USD
CY2016Q3	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	-74000	USD
CY2016Q3	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	62000	USD
CY2016Q3	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	185000	USD
CY2015Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	147000	USD
CY2015	us-gaap	Standard Product Warranty Accrual Payments StandardProductWarrantyAccrualPayments	-81000	USD
CY2015	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	-24000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6744000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6090000	USD
	dei	Entity Central Index Key EntityCentralIndexKey	0001123494
	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	-31000	USD
CY2016Q3	us-gaap	Secured Debt SecuredDebt	15042000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	21920000	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	16018000	USD
CY2015Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	10957000	USD
CY2015Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	888000	USD
CY2015Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	10498000	USD
CY2016Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	47179000	USD
CY2016Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-28318000	USD
CY2015Q4	hbio	Total Indefinite Lived Intangible Assets Including Goodwill TotalIndefiniteLivedIntangibleAssetsIncludingGoodwill	41580000	USD
CY2015Q4	hbio	Total Intangible Assets TotalIntangibleAssets	89159000	USD
CY2014Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	252000	USD
CY2016Q3	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	0	USD
CY2015Q3	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	0	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	1095190	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.4197	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.4107	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0129	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0172	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y3M7D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y6M7D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation ShareBasedCompensation	2596000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2049000	USD
CY2016Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34327459	shares
CY2015Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33933327	shares
CY2016Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2015Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2016Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34327459	shares
CY2015Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33933327	shares
CY2015Q2	hbio	Increase In Number Of Shares Authorized For Issuance Under Stock Option And Incentive Plan IncreaseInNumberOfSharesAuthorizedForIssuanceUnderStockOptionAndIncentivePlan	2500000	shares
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	32000	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	47579000	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-26707000	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	17547000	USD
CY2015Q4	us-gaap	Assets Assets	120050000	USD
CY2015Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	1223000	USD
CY2015Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3873000	USD
CY2015Q4	us-gaap	Inventory Net InventoryNet	22343000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	995000	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	20872000	USD
CY2015Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	310000	USD
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41724772	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	33979265	shares
CY2015Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	7745507	shares
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	42000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	50549000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	152000	USD
CY2015Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	2364000	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8782000	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	752000	USD
CY2015Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	290000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4021000	USD
CY2015Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	868000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19323000	USD
CY2015Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	16369000	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	3775000	USD
CY2015Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	2985000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	42452000	USD
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	416000	USD
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	211457000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-111723000	USD
CY2015Q4	us-gaap	Treasury Stock Carrying Basis TreasuryStockCarryingBasis	10668000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	120050000	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Current DeferredTaxLiabilitiesCurrent	2246000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5902000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	77598000	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5022186	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	313559	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	5.29
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5200000	USD
CY2016Q3	us-gaap	Revenues Revenues	25007000	USD
CY2016Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	13317000	USD
CY2016Q3	us-gaap	Gross Profit GrossProfit	11690000	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	12503000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-813000	USD
CY2016Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-67000	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-880000	USD
CY2016Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	758000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-1638000	USD
CY2016Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2016Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
	us-gaap	Goodwill Translation Adjustments GoodwillTranslationAdjustments	-783000	USD
	us-gaap	Description Of New Accounting Pronouncements Not Yet Adopted DescriptionOfNewAccountingPronouncementsNotYetAdopted	<div><p style='text-align:left;margin-top:9pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:0pt;' >2</font><font style='font-family:Times New Roman;font-size:10pt;font-weight:bold;' >.</font><font style='font-family:Times New Roman;font-size:10pt;font-weight:bold;' > Recently Issued Accounting Pronouncements</font></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Calibri;font-size:11pt;font-weight:bold;margin-left:0pt;' > </font></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;' >In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, </font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;' >“Revenue from Contracts with Customers,”</font><font style='font-family:Times New Roman;font-size:10pt;' > a new accounting standard that provides for a comprehensive model to use in the accounting for revenue arising from contracts with customers that will replace most existing revenue recognition guidance within generally accepted accounting principles in th</font><font style='font-family:Times New Roman;font-size:10pt;' >e United States. Under this standard, revenue will be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or servi</font><font style='font-family:Times New Roman;font-size:10pt;' >ces. At its July 2015 meeting, the FASB agreed to defer the mandatory effective date of ASU 2014-09 one year. Under the one year deferral, the standard will take effect in 2018 for calendar ye</font><font style='font-family:Times New Roman;font-size:10pt;' >ar-end public entities. </font></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;' > </font></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;' >In July 2015, the FASB issued ASU 201</font><font style='font-family:Times New Roman;font-size:10pt;' >5-11, </font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;' >Simplifying Measurement of Inventory</font><font style='font-family:Times New Roman;font-size:10pt;' >. The update requires measurement of most inventory “at the lower of cost and net realizable value”, and applies to all entities that recognize inventory within the scope of ASC 330, except for inventory measured u</font><font style='font-family:Times New Roman;font-size:10pt;' >nder the last-in, first-out (LIFO) method or the retail inventory method (RIM). ASU 2015-11 requires prospective application and represents a change in accounting principle. The update is effective for fiscal years beginning after December 15, 2016.  Early</font><font style='font-family:Times New Roman;font-size:10pt;' > adoption is permitted for financial statements that have not been prev</font><font style='font-family:Times New Roman;font-size:10pt;' >iously issued. </font></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;' > </font></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;' >In February 2016, the FASB issued ASU 2016-02, </font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;' >Leases</font><font style='font-family:Times New Roman;font-size:10pt;' >, which is intended to improve financial reporting about leasing transactions. The update requires a lessee to rec</font><font style='font-family:Times New Roman;font-size:10pt;' >ord on the balance sheet the assets and liabilities for the rights and obligations created by lease terms of more than 12 months. The update is effective for fiscal years beginning after December 15, 2018. </font></p><p style='text-align:left;line-height:12pt;' ></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;color:#000000;' >In March 2016, the FASB issued ASU 2016-09, </font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;color:#000000;' >Comp</font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;color:#000000;' >ensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >, which simplifies the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or li</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >abilities and classification on the statement of cash flows. </font><font style='font-family:Times New Roman;font-size:10pt;' >The update is effective for fiscal years be</font><font style='font-family:Times New Roman;font-size:10pt;' >ginning after December 15, 2016 </font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >and early adoption is permitted. </font></p><p style='text-align:left;line-height:12pt;' ></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;' >In June 2016, the FASB issued ASU 2016-13, </font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;' >Financial Instruments – Credit Losses (Topic 326), Measurement of credit losses on Financial Instruments. </font><font style='font-family:Times New Roman;font-size:10pt;' >The update</font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;' > </font><font style='font-family:Times New Roman;font-size:10pt;' >amends the FASB</font><font style='font-family:Times New Roman;font-size:10pt;' >’s guidance on the impairment of financial instruments. The ASU adds to U.S. GAAP an impairment model (known as the current </font><font style='font-family:Times New Roman;font-size:10pt;' >expected credit loss (CECL) model) that is based on expected losses rather than incurred losses. Under the new guidance, an entity recognizes as an allowance its estimate of expected credit losses, which the FASB believes will result in more ti</font><font style='font-family:Times New Roman;font-size:10pt;' >mely recogni</font><font style='font-family:Times New Roman;font-size:10pt;' >tion of such losses. </font><font style='font-family:Times New Roman;font-size:10pt;' >The ASU is effective for fiscal years beginning after December 15, 2019, </font><font style='font-family:Times New Roman;font-size:10pt;' >including interim periods within those fiscal years.</font></p><p style='text-align:left;line-height:12pt;' ></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;' >In August</font><font style='font-family:Times New Roman;font-size:10pt;' > 2016, the FASB issued</font><font style='font-family:Times New Roman;font-size:10pt;' > ASU 2016-15, </font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;' >Classification of Certain Cash Receipts and Cash Payments (Topi</font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;' >c 230)</font><font style='font-family:Times New Roman;font-size:10pt;' > which </font><font style='font-family:Times New Roman;font-size:10pt;' >amends ASC 2</font><font style='font-family:Times New Roman;font-size:10pt;' >30,</font><sup><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;' > </font></sup><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;' >Statement of Cash Flows</font><font style='font-family:Times New Roman;font-size:10pt;' > to add or clarify guidance on the classification of certain cash receipts and payments in the statement of cash flows. </font><font style='font-family:Times New Roman;font-size:10pt;' >T</font><font style='font-family:Times New Roman;font-size:10pt;' >he guidance is effective for fiscal years beginning after December 15, 2017, includ</font><font style='font-family:Times New Roman;font-size:10pt;' >ing interim periods within those fiscal years.</font><font style='font-family:Times New Roman;font-size:10pt;' > </font></p><p style='text-align:left;line-height:12pt;' ></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;' >The Company is evaluating the impact of each of </font><font style='font-family:Times New Roman;font-size:10pt;' >ASU 2014-09, ASU 2015-11, ASU 2016-02, </font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >ASU 2016-09, </font><font style='font-family:Times New Roman;font-size:10pt;' >ASU 2016-13 and </font><font style='font-family:Times New Roman;font-size:10pt;' >ASU 2016-15 on its consolidated financial statements.</font></p><p style='text-align:left;line-height:12pt;' ></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:24.5pt;' >Recently Adopted Accounting Pronounc</font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;' >ements</font></p><p style='text-align:left;line-height:12pt;' ></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:inherit;font-size:10pt;margin-left:24.5pt;' >In April 2015, the FASB issued ASU 2015-03, </font><font style='font-family:inherit;font-size:10pt;font-style:italic;' >Interest - Imputation of Interest - Simplifying the Presentation of Debt Issuance Costs</font><font style='font-family:inherit;font-size:10pt;' >. Under this guidance, debt issuance costs related to a recognized debt liability should be presented</font><font style='font-family:inherit;font-size:10pt;' > in the balance sheet as a direct deduction from the carrying amount of that debt liability. The provisions of this guidance are to be applied retrospectively and are effective for interim and annual periods beginning after December 15, 2015. The Company a</font><font style='font-family:inherit;font-size:10pt;' >dopted this guidance during the </font><font style='font-family:inherit;font-size:10pt;' >nine months ended</font><font style='font-family:inherit;font-size:10pt;' > </font><font style='font-family:inherit;font-size:10pt;' >September 30,</font><font style='font-family:inherit;font-size:10pt;' > </font><font style='font-family:inherit;font-size:10pt;' >2016</font><font style='font-family:inherit;font-size:10pt;' >. The consolidated balance sheet as of December 31, </font><font style='font-family:inherit;font-size:10pt;' >2015</font><font style='font-family:inherit;font-size:10pt;' >, included in these consolidated financial statements, reflects a restatement to reclassify unamortized deferred fina</font><font style='font-family:inherit;font-size:10pt;' >ncing costs of approximately $0.2 million from other long-term assets to long-term debt. For deferred financing costs paid to secure long-term debt, the Company made a policy election to present such costs as a direct deduction from the debt liability on t</font><font style='font-family:inherit;font-size:10pt;' >he consolidated balance sheet.</font></p><p style='text-align:left;line-height:12pt;' ></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;' >In September 2015, the FASB issued ASU 2015-16</font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;' >, </font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;' >Simplifying</font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;' > the Accounting for Measurement-Period Adjustments</font><font style='font-family:Times New Roman;font-size:10pt;' >. The update eliminates the requirement to retrospectively adjust financial statements for measurement-period adjustments that occur in periods after a business combination. Un</font><font style='font-family:Times New Roman;font-size:10pt;' >der the update, measurement-period adjustments are to be calculated as if they were known at the acquisition date, but are recognized in the reporting period in which they are determined. Additional disclosures are required about the impact on current-period earnings. ASU 2015-16 requires prospective application to adjustments of provisional amounts that occur after the effective date. The update was effective for fiscal years beginning after December 15, 2015.  The Company adopted ASU 2015-16 on January 1, 2016. The adoption of ASU 2015-16 did not have a material impact on its consolidated financial statements.</font></p><p style='text-align:left;line-height:12pt;' ></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;' >In November 2015, the FASB issued ASU 2015-17, </font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;' >Balance Sheet Classification of Deferred Taxes</font><font style='font-family:Times New Roman;font-size:10pt;' >. The update requires all deferred income taxes to be presented on the balance sheet as noncurrent. The new guidance is intended to</font><font style='font-family:Times New Roman;font-size:10pt;' > simplify financial reporting by eliminating the requirement to classify deferred taxes between current and noncurrent. The update is effective for fiscal years beginning after December 15, 2016.  Early adoption is permitted at the beginning of an interim </font><font style='font-family:Times New Roman;font-size:10pt;' >or annual period. </font><font style='font-family:Times New Roman;font-size:10pt;' >During the </font><font style='font-family:Times New Roman;font-size:10pt;' >nine months ended</font><font style='font-family:Times New Roman;font-size:10pt;' > </font><font style='font-family:Times New Roman;font-size:10pt;' >September 30,</font><font style='font-family:Times New Roman;font-size:10pt;' > </font><font style='font-family:Times New Roman;font-size:10pt;' >2016</font><font style='font-family:Times New Roman;font-size:10pt;' >, t</font><font style='font-family:Times New Roman;font-size:10pt;' >he Company </font><font style='font-family:Times New Roman;font-size:10pt;' >early adopted the new guidance on a prospective basis and has presented all deferred tax assets and deferred tax liabilities as noncurrent in the consolidated balance sheet</font><font style='font-family:Times New Roman;font-size:10pt;' > at </font><font style='font-family:Times New Roman;font-size:10pt;' >September 30,</font><font style='font-family:Times New Roman;font-size:10pt;' > </font><font style='font-family:Times New Roman;font-size:10pt;' >2016</font><font style='font-family:Times New Roman;font-size:10pt;' >.</font></p></div>
	us-gaap	Standard Product Warranty Accrual Payments StandardProductWarrantyAccrualPayments	-56000	USD
	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	94000	USD
CY2015Q3	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	175000	USD
CY2015Q3	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	165000	USD
CY2015Q3	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	-75000	USD
CY2015Q3	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	85000	USD
CY2016Q3	us-gaap	Defined Benefit Plans Estimated Future Employer Contributions In Current Fiscal Year DefinedBenefitPlansEstimatedFutureEmployerContributionsInCurrentFiscalYear	300000	USD
CY2016Q3	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	200000	USD
CY2015Q3	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	200000	USD
CY2016Q3	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	2600000	USD
CY2015Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	2800000	USD
CY2016Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	500000	USD
CY2015Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	600000	USD
CY2016Q3	hbio	Minimun Percentage Of Term Loan And Delayed Draw Term Loan On Which Interest Rate Required To Be Fixed MinimunPercentageOfTermLoanAndDelayedDrawTermLoanOnWhichInterestRateRequiredToBeFixed	0.5	pure
CY2016Q3	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	-120000	USD
CY2015Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	-167000	USD
CY2016Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5300945	shares
CY2015Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5640536	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	17508929	shares
CY2016Q3	hbio	Weighted Average Estimated Black Scholes Value Of Option Grants WeightedAverageEstimatedBlackScholesValueOfOptionGrants	1.11
CY2015Q3	hbio	Weighted Average Estimated Black Scholes Value Of Option Grants WeightedAverageEstimatedBlackScholesValueOfOptionGrants	2.14
	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	530000	USD
	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	492000	USD
	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	-233000	USD
	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	195000	USD
	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	542000	USD
	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	510000	USD
	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	-231000	USD
	us-gaap	Defined Benefit Plan Recognized Net Gain Loss Due To Curtailments DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments	0	USD
	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	263000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4888000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2137000	USD
	us-gaap	Operating Expenses OperatingExpenses	37625000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1826000	USD
	us-gaap	Interest Expense InterestExpense	641000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	159000	USD
	us-gaap	Other Interest And Dividend Income OtherInterestAndDividendIncome	5000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-984000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1461000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-3287000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1388000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-1899000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-3263000	USD
	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-110000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	41796000	USD
	us-gaap	Gross Profit GrossProfit	36310000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	15194000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15984000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4236000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2099000	USD
	us-gaap	Operating Expenses OperatingExpenses	38184000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1874000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	411000	USD
	us-gaap	Interest Expense InterestExpense	486000	USD
	us-gaap	Other Interest And Dividend Income OtherInterestAndDividendIncome	2000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-143000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-216000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-2090000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	897000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-1390000	USD
	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-37000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-31000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-72000	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
	us-gaap	Revenues Revenues	78106000	USD
	us-gaap	Revenues Revenues	80294000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	44495000	USD
	us-gaap	Gross Profit GrossProfit	35799000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	15355000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14758000	USD
	dei	Document Period End Date DocumentPeriodEndDate	2016-09-30
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2015Q3	hbio	Business Acquisition Direct Acquisition Costs In Income Statement BusinessAcquisitionDirectAcquisitionCostsInIncomeStatement	200000	USD
	hbio	Business Acquisition Direct Acquisition Costs In Income Statement BusinessAcquisitionDirectAcquisitionCostsInIncomeStatement	900000	USD
	us-gaap	Goodwill Other Changes GoodwillOtherChanges	50000	USD
CY2016Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-13280000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4383000	USD
	hbio	Estimated Rental Expenses Current Year EstimatedRentalExpensesCurrentYear	1900000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1800000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1400000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-11884000	USD
	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	-1427000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1396000	USD
	us-gaap	Defined Benefit Plans Estimated Future Employer Contributions In Current Fiscal Year DefinedBenefitPlansEstimatedFutureEmployerContributionsInCurrentFiscalYear	300000	USD
	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	500000	USD
	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	600000	USD
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.4305	pure
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.3947	pure
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0176	pure
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2016Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y1M28D
CY2015Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y3M10D
CY2016Q3	us-gaap	Share Based Compensation ShareBasedCompensation	943000	USD
CY2015Q3	us-gaap	Share Based Compensation ShareBasedCompensation	777000	USD
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	-374772	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34156606	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33473958	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34156606	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33473958	shares
CY2016Q3	hbio	Percentage Of Outstanding Common Stock PercentageOfOutstandingCommonStock	0.2	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Offering Date ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate	0.85	pure
CY2016Q3	hbio	Employee Stock Purchase Plan Shares Authorized EmployeeStockPurchasePlanSharesAuthorized	750000	shares
CY2016Q3	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	39353	shares
CY2015Q3	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	26181	shares
	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	683364	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5300945	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5640536	shares
	hbio	Weighted Average Estimated Black Scholes Value Of Option Grants WeightedAverageEstimatedBlackScholesValueOfOptionGrants	1.21
	hbio	Weighted Average Estimated Black Scholes Value Of Option Grants WeightedAverageEstimatedBlackScholesValueOfOptionGrants	2.21
CY2015Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
	hbio	Additions To Catalog Costs AdditionsToCatalogCosts	34000	USD
	hbio	Additions To Catalog Costs AdditionsToCatalogCosts	0	USD
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.1
CY2015Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	3850
CY2016Q3	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	600000	USD
	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	600000	USD
	us-gaap	Restructuring Charges RestructuringCharges	487000	USD
	us-gaap	Restructuring Charges RestructuringCharges	-5000	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6090000	USD
CY2016Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	676000	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	676000	USD

Files In Submission

Name	View Source	Status
0001171843-16-012917-index-headers.html	Edgar Link	pending
0001171843-16-012917-index.html	Edgar Link	pending
0001171843-16-012917.txt	Edgar Link	pending
0001171843-16-012917-xbrl.zip	Edgar Link	pending
exh_311.htm	Edgar Link	pending
exh_312.htm	Edgar Link	pending
exh_321.htm	Edgar Link	pending
exh_322.htm	Edgar Link	pending
f10q_110316.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
hbio-20160930.xml	Edgar Link	completed
hbio-20160930.xsd	Edgar Link	pending
hbio-20160930_cal.xml	Edgar Link	unprocessable
hbio-20160930_def.xml	Edgar Link	unprocessable
hbio-20160930_lab.xml	Edgar Link	unprocessable
hbio-20160930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HBIO
HARVARD BIOSCIENCE INC Stock $hbio

2016 Q4 Form 10-Q Financial Statement

#000117184316012917 Filed on November 03, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HBIO HARVARD BIOSCIENCE INC Stock $hbio

2016 Q4 Form 10-Q Financial Statement

#000117184316012917 Filed on November 03, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HBIO
HARVARD BIOSCIENCE INC Stock $hbio